Celgene International Sárl (CELG) Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
5/23/2013
More...
|
Zensun Announces Positive Clinical Results for Neucardin™ to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients
5/23/2013
More...
|
TauRx Therapeutics Release: First UK Patients Enroll in Phase 3 Clinical Trials of LMTX™ for Alzheimer's Disease
5/23/2013
More...
|
Takeda Pharmaceutical Co. Ltd. (TKPYY) Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients With Newly Diagnosed Multiple Myeloma
5/23/2013
More...
|
Opko Health, Inc. Surpasses 50% Enrollment in First Phase 3 Trial of Rayaldy™ (CTAP101 Capsules)
5/23/2013
More...
|
Novo Nordisk A/S (NVO) Reports 8% Weight Loss in Phase 3a Obesity Trial With liraglutide 3 mg
5/23/2013
More...
|
OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination With Chemotherapy in Advanced Squamous Cell Lung Cancer
5/23/2013
More...
|
Lpath, Inc. Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
5/23/2013
More...
|
Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
5/23/2013
More...
|
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Running Phase 2b Trial of Proellex®-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
5/23/2013
More...
|
Lightlake Therapeutics Inc. (LLTP)’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting
5/23/2013
More...
|
Promedior Presents Encouraging Results From Clinical Study of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
5/23/2013
More...
|
Virobay Inc. Initiates a Phase 1 Trial of VBY-036, a Compound Intended for the Treatment of Neuropathic Pain
5/23/2013
More...
|
Spring Bank Pharmaceuticals, Inc. Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
5/23/2013
More...
|
First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder
5/23/2013
More...
|
Omeros Corporation (OMER) Release: Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
5/23/2013
More...
|
Arsanis, Inc. Nominates Preclinical Candidate for Staphylococcus aureus Program
5/23/2013
More...
|
Pamlab LLC: New Research Highlights Biological and Genetic Markers Associated With Improved Response to Adjunctive L-Methylfolate in Management of Depression
5/23/2013
More...
|
MEDA: Dymista Reimbursed in Sweden
5/23/2013
More...
|